CIALIS (tadalafil) by Eli Lilly and Company is phosphodiesterase 5 inhibitors [moa]. Approved for phosphodiesterase 5 inhibitor [epc]. First approved in 2003.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
CIALIS (tadalafil) is an oral phosphodiesterase 5 (PDE5) inhibitor approved in 2003 for erectile dysfunction and other indications. It works by relaxing smooth muscle and increasing blood flow to the penis, enabling sustained erections. The drug is available as tablets and represents a mature, well-established therapeutic option in the PDE5 inhibitor class.
Approaching loss of exclusivity with modest Part D spending; brand team focus shifting toward line extensions, cost management, and transition planning.
Phosphodiesterase 5 Inhibitors
Phosphodiesterase 5 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis
Actual Use Trial of Tadalafil 5 mg
Impact of Dental Desensitization Facilitated by a Child Life Specialist Distress and Cooperation
Worked on CIALIS at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCIALIS offers limited growth career opportunities given its LOE-approaching status and minimal current job openings. Roles available tend to focus on brand defense, generic transition management, and cost/access optimization rather than expansion or launch activities.